---
title: "Deflazacort - Duchenne Muscular Dystrophy"
sidebar: mydoc_sidebar
permalink: db11921-mesh-d020388-1.html
toc: false 
---


Path ID: `DB11921_MESH_D020388_1`
{% include image.html url="images/db11921-mesh-d020388-1.png" file="db11921-mesh-d020388-1.png" alt="db11921-mesh-d020388-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C021988 | deflazacort | Drug |
| DB:DBMET02573 | 21-deflazacort | ChemicalSubstance |
| UniProt:P04150 | Glucocorticoid receptor | Protein |
| GO:0006954 | inflammatory response | BiologicalProcess |
| HP:0003323 | Progressive muscle weakness | PhenotypicFeature |
| MESH:D020388 | Duchenne muscular dystrophy | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Deflazacort | HAS METABOLITE | 21-Deflazacort |
| 21-Deflazacort | POSITIVELY REGULATES | Glucocorticoid Receptor |
| Glucocorticoid Receptor | NEGATIVELY REGULATES | Inflammatory Response |
| Inflammatory Response | CORRELATED WITH | Progressive Muscle Weakness |
| Progressive Muscle Weakness | MANIFESTATION OF | Duchenne Muscular Dystrophy |
|---------|-----------|---------|

Comment: The exact mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown but likely occurs via its anti-inflammatory activities.

Reference: 
  - [https://go.drugbank.com/drugs/DB11921](https://go.drugbank.com/drugs/DB11921)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201891/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201891/)
  - [https://pubchem.ncbi.nlm.nih.gov/compound/189821](https://pubchem.ncbi.nlm.nih.gov/compound/189821)
  - [https://en.wikipedia.org/wiki/Deflazacort#Mechanism_of_action](https://en.wikipedia.org/wiki/Deflazacort#Mechanism_of_action)
  - [https://en.wikipedia.org/wiki/Glucocorticoid#Mechanism_of_action](https://en.wikipedia.org/wiki/Glucocorticoid#Mechanism_of_action)
